		2003/08/27	USPAT; EPO; JPO; DERWENT	same ((poly adj (lactide-co-glycolide)) or (poly adj adj (glycolide)) or (poly adj (lactic adj acid)) or (poly adj ((lactic adj acid)-co-(glycolic adj acid))) or (polyanhydride or polyorthoester or polyetherester or polyesteramide or (polyethylene adj glycol)))	2805	L8	BRS	∞
		2003/08/27 16:50	USPAT; EPO; JPO; DERWENT	microsphere or microparticle	31536	L7	BRS	7
		2003/08/27 16:50		polyanhydride or polyorthoester or polyetherester or polycaprolactone o polyesteramide or (polyethylene adj glycol)	423585 4	L6	BRS	6
:		2003/08/27 16:49	USPAT; EPO; JPO; DERWENT	poly adj ((lactic adj acid)-co-(glycolic adj acid))	2116	L5	BRS	5
		2003/08/27 16:49	USPAT; EPO; JPO; DERWENT	poly adj (lactic adj acid)	1934	L4	BRS	4
		2003/08/27 16:48	USPAT; EPO; JPO; DERWENT	poly adj (glycolide)	445	L3	BRS	ω
,		2003/08/27 16:47	USPAT; EPO; JPO; DERWENT	poly adj (lactide-co-glycolide)	124	L2	BRS	2
		2003/08/27 16:46	USPAT; EPO; JPO; DERWENT	(hyaluronic adj acid) or hyaluronate	8024	L1	BRS	1
	Comm	Time Stamp	DBs	Search Text	Hits	L#	Туре	

		· · · · · · · · · · · · · · · · · · ·	· 
	10	9	
BRS	BRS	BRS	Туре
	L10	<b>1</b> 9	L#
55	441	28	Hits
(((hyaluronic adj acid) or hyaluronate) same buffer) same ((poly adj (lactide-co-glycolide)) or (poly adj (lactic adj acid)) or (poly adj (lactic adj acid)) or (poly adj ((lactic adj acid)) or (poly adj ((lactic adj acid))) or (polyanhydride or polyetherester or polyetherester or polyetherester or polyesteramide or (polyethylene adj glycol)))	((hyaluronic adj acid) or hyaluronate) same buffer	((hyaluronic adj acid) or hyaluronate) same ( (microsphere or microparticle) same ((poly adj (lactide-co-glycolide)) or (poly adj (lactic adj acid)) or (poly adj (lactic adj acid)-co-(glycolic adj acid))) or (polyadj (microspolycolic adj acid))) or (polyanhydride or polyorthoester or polyetherester or polyesteramide or (polyethylene adj glycol))))	Search Text
USPAT; EPO; JPO; DERWENT	USPAT; EPO; JPO; DERWENT	USPAT; EPO; JPO; DERWENT	DBs
2003/08/27	2003/08/27 17:02	2003/08/27	Time Stamp
			Comm ents
			Err or Defi nitio
0	0	0	Err

14	13	12	
BRS	BRS	BRS	Туре
L14	L13	L12	L#
2	30	<b>}</b>	Hits
( ((hyaluronic adj acid) or hyaluronate ) near ( buffer or saline)) same ( microsphere or microparticle)	((hyaluronic adj acid) or hyaluronate) near (buffer or saline)	(((hyaluronic adj acid) or hyaluronate) same buffer) same ((poly adj (lactide-co-glycolide)) or (poly adj (lactic adj acid)) or (poly adj (lactic adj acid)) or (poly adj (lactic adj acid)) or (poly adj ((lactic adj acid))) or (polyanhydride or polyanhydride or polyetherester or polyesteramide or (polyethylene adj glycol))) same (microsphere or microparticle)	Search Text
USPAT; EPO; JPO; DERWENT	USPAT; EPO; JPO; DERWENT	USPAT; EPO; JPO; DERWENT	DBs
2003/08/27 17:04	2003/08/27 17:03	2003/08/27	Time Stamp
			Comm
			Err or Defi nitio
0	0	0	Err

16 H	15 H	
BRS	BRS	Туре
L16	L15	L #
3381	0	Hits
(microsphere or microparticle) same (((hyaluronic adj acid) or hyaluronate) or (poly adj (lactide-co-glycolide)) or (poly adj (adj (glycolide)) or (poly adj (lactic adj acid)) or (poly adj ((lactic adj acid)-co-(glycolic adj acid))) or (polyanhydride or polyorthoester or polyetherester or polycaprolactone o polyesteramide or (polyethylene adj glycol)))	( ((hyaluronic adj acid) or hyaluronate ) near ( buffer or saline)) same ( ( microsphere or microparticle) same ((poly adj (lactide-co-glycolide) ) or (poly adj (lactic adj acid) ) or (poly adj (lactic adj acid)-co-(glycolic adj acid))) or (polyanhydride or polyorthoester or polyetherester or polyesteramide or (polyethylene adj glycol))))	Search Text
USPAT; EPO; JPO; DERWENT	USPAT; EPO; JPO; DERWENT	DBs
2003/08/27	2003/08/27	Time Stamp Con
		Err nm Defi ts nitio
0	0	Err

0		2003/08/27	USPAT; EPO; JPO; DERWENT	((microsphere or microparticle) same buffer same ((hyaluronic adj acid) or hyaluronate)) same ((poly adj (lactide-co-glycolide)) or (poly adj (lactic adj acid)) or (poly adj (lactic adj acid)-co-(glycolic adj acid))) or (poly adj (poly adj acid)) or (poly adj (poly adj acid))) or (poly adj acid) or (polyanhydride or polyorthoester or polyetherester or polyesteramide or (polyethylene adj glycol)))	<b>}</b>	L19	BRS	19
0		2003/08/27 17:05	USPAT; EPO; JPO; DERWENT	( microsphere or microparticle) same buffer same ((hyaluronic adj acid) or hyaluronate)	2	L18	BRS	18
0		2003/08/27 17:05	USPAT; EPO; JPO; DERWENT	microsphere or (((hyaluronic adj acid) or hyaluronate) or (poly adj (lactide-co-glycolide)) or (poly adj (glycolide)) or (poly adj (lactic adj acid) or (poly adj ((lactic adj acid)-co-(glycolic adj acid))) or (polyanhydride or polyorthoester or polyetherester or polycaprolactone o polyesteramide or (polyethylene adj glycol)))) same (buffer or saline)	150	L17	BRS	17
rr fi Err io ors	Comm Defi ents nitio	Time Stamp	DBs	Search Text	Hits	L#	Туре	

0			2003/08/27	JPO; DERWENT	(25 or 26 or 27) and 1 and 7	1	L28	BRS	28
0			2003/08/27 17:16	USPAT; EPO; JPO; DERWENT	okumu adj franklin.in.	<b>—</b>	L27	BRS	27
0			2003/08/27 17:16	USPAT; EPO; JPO; DERWENT	lam adj xanthe.in.	8	L26	BRS	26
0			2003/08/27 17:15	USPAT; EPO; JPO; DERWENT	cleland adj jeffrey.in.	14	L25	BRS	25
0			2003/08/27 17:15	USPAT; EPO; JPO; DERWENT	23 same 1	3	L24	BRS	24
0			2003/08/27 17:11	USPAT; EPO; JPO; DERWENT	7 same 22	46	L23	BRS	23
0			2003/08/27 17:10	USPAT; EPO; JPO; DERWENT	vegf or ngf or (nutropin adj depot)	5239	L22	BRS	22
0			2003/08/27 17:09	USPAT; EPO; JPO; DERWENT	7 same 20	0	L21	BRS	21
0			2003/08/27 17:08	USPAT; EPO; JPO; DERWENT	amvisc adj plus	3	L20	BRS	20
Err	Err n or Defi nitio	Comn	Time Stamp	DBs	Search Text	Hits	L #	Туре	

```
FILE 'MEDLINE' ENTERED AT 17:26:32 27 AUG 2003
FILE 'CAPLUS' ENTERED AT 17:26:32 ON 27 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOSIS' ENTERED AT 17:26:32 ON 27 AUG 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)
FILE 'EMBASE' ENTERED AT 17:26:32 ON 27 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.
FILE 'SCISEARCH' ENTERED AT 17:26:32 ON 27 AUG 2003
COPYRIGHT 2003 THOMSON ISI
FILE 'AGRICOLA' ENTERED AT 17:26:32 ON 27 AUG 2003
=> s (hyaluronic acid) or hyaluronate
         49541 (HYALURONIC ACID) OR HYALURONATE
=> s poly(lactide-co-glycolide)
MISSING OPERATOR 'POLY(LACTIDE-CO'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
=> s poly (w)(lactide-co-glycolide)
          2147 POLY (W) (LACTIDE-CO-GLYCOLIDE)
=> s poly (w) glycolide
          479 POLY (W) GLYCOLIDE
=> s poly (w) (lactic acid)
          5055 POLY (W) (LACTIC ACID)
=> s poly (w) ((lactic acid)-co-(glycolic acid))
MISSING OPERATOR ACID)-CO-
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
=> s poly (w) (lactic acid)(w) co (w) (glycolic acid)
            93 POLY (W) (LACTIC ACID) (W) CO (W) (GLYCOLIC ACID)
=> s polyanhydride or polyorthoester or polyetherester or polycaprolactone or polyesteramide or (p
        147014 POLYANHYDRIDE OR POLYORTHOESTER OR POLYETHERESTER OR POLYCAPROLA
L6
               CTONE OR POLYESTERAMIDE OR (POLYETHYLENE GLYCOL)
=> s 12 or 13 or 14 or 15 or 16
        153734 L2 OR L3 OR L4 OR L5 OR L6
=> s microsphere or microparticle
        102649 MICROSPHERE OR MICROPARTICLE
=> s 17 (p) 18
          3141 L7 (P) L8
=> s l1 (a) (buffer or saline)
            15 L1 (A) (BUFFER OR SALINE)
L10
=> s 19 (p) 110
            0 L9 (P) L10
L11
=> s 19 (p) 11
             2 L9 (P) L1
L12
=> duplicate remove 112
DUPLICATE PREFERENCE IS 'CAPLUS, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L12
L13
              2 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)
=> d 113 1-2 ibib abs
L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
                         2002:978348 CAPLUS
ACCESSION NUMBER:
```

138:44739

DOCUMENT NUMBER:

Sustained\_release of drugs encapsulated in TITLE: micropart es of hyaluronic acid Kim, Myung-jin; Kim, Sun-jin; Kwon, Oh-ryong INVENTOR(S): LG Chemical Limited, S. Korea PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. SOURCE: Ser. No. 596,593. CODEN: USXXCO DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: APPLICATION NO. DATE DATE PATENT NO. KIND us 2002-205954 20020726 20021226 US 2002197328 A1 KR 1997-12046 A 19970401 PRIORITY APPLN. INFO.: B2 19981130 us 1998-194653 us 2000-596593 A2 20000619 A sustained-release drug compn. consists essentially of microparticles of AB hyaluronic acid having ā high mol. wt. or an inorg. salt and a protein or peptide drug encapsulated in the microparticles, wherein the av. size of the microparticles ranges from 0.1 to 40 .mu.m. To a 5-mM phosphate-buffered saline contg. 1 mg/mL of hGH, Tween 80 was added to a concn. of 0.01%. Sodium hyaluronate having a mol. wt. of 2,000,000 was added thereto to a concn. of 1 mg/mL. The resulting soln. was supplied to a spray-dryer at a rate of 2 mL/min. to prep. microparticles. The temp. of the influx air to the spray dryer was 85.degree.. The mean diam. of the microparticles thus obtained was 2.0 .mu.m. SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN L13 ANSWER 2 OF 2 2002:716522 SCISEARCH ACCESSION NUMBER: THE GENUINE ARTICLE: 584MR Composition options for tissue-engineered bone TITLE: Orban J M; Marra K G; Hollinger J O (Reprint) **AUTHOR:** Carnegie Mellon Univ, Bone Tissue Engn Ctr, 125 Smith CORPORATE SOURCE: Hall, 5000 Forbes Ave, Pittsburgh, PA 15213 USA (Reprint); Carnegie Mellon Univ, Bone Tissue Engn Ctr, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Inst Complex Engineered Syst, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biomed Engn, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA COUNTRY OF AUTHOR: USA TISSUE ENGINEERING, (AUG 2002) Vol. 8, No. 4, pp. 529-539. SOURCE: Publisher: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY 10538 USA. ISSN: 1076-3279. General Review; Journal DOCUMENT TYPE: English LANGUAGE: 123 REFERENCE COUNT: \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\* The logical assembly of tissue-engineered bone is ultimately directed AB by the clinical status of the patient. The basic elements for tissue-engineered bone should include signaling molecules, cells, and extracellular matrix. The assembly of these basic elements may need to be modified by tissue engineers to account for patient variables of age, gender, health, systemic conditions, habits, and anatomical implant. Moreover, different regions of the body will have different functional loads and vascularity. This review discusses several basic options that may be necessary to engineer bone, including spatial and temporal assembly of signaling factors, cells, and biomimetic extracellular matrices. Moreover, the importance of the health care status of the patient who may be receiving the tissue-engineered composition is emphasized. => d his (FILE 'HOME' ENTERED AT 17:26:07 ON 27 AUG 2003) FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 17:26:32 ON 27 AUG 2003 49541 S (HYALURONIC ACID) OR HYALURONATE L1 2147 S POLY (W) (LACTIDE-CO-GLYCOLIDE) L2 479 S POLY (W) GLYCOLIDE L3 5055 S POLY (W) (LACTIC ACID) **L4** 93 S POLY (W) (LACTIC ACID)(W) CO (W) (GLYCOLIC ACID) L5

147014 S POLYANHYDRIDE OR POLYORTHOESTER OR POLYETHERESTER OR POLYCAPR

153734 S L2 OR L3 OR L4 OR L5 OR L6

**L6** 

L7

```
3141 S L7 (P) L8
L9
             15 S L1 (A) (BUFFER OR SALINE)
L10
             0 S L9 (P) L10
L11
              2 S L9 (P) L1
L12
              2 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)
L13
=> s 110 (p) 18
             0 L10 (P) L8
L14
=> s cleland jeffrey/au
             5 CLELAND JEFFREY/AU
L15
=> s lam xanthe/au
             9 LAM XANTHE/AU
L16
=> s okumu franklin/au
             6 OKUMU FRANKLIN/AU
L17
=> s (115 or 116 or 117) and 11 and 18
             1 (L15 OR L16 OR L17) AND L1 AND L8
L18
=> d 118 1 ibib abs
L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS ON STN
ACCESSION NUMBER:
                         2001:300548 CAPLUS
                         134:316141
DOCUMENT NUMBER:
                         Injection vehicle for polymer-based formulations
TITLE:
                         Cleland, Jeffrey L.; Lam, Xanthe M.; ***Okumu, ***
INVENTOR(S):
                              Franklin***
                         Genetech, Inc., USA
PATENT ASSIGNEE(S):
                         PCT Int. Appl., 26 pp.
SOURCE:
                         CODEN: PIXXD2
                         Patent
DOCUMENT TYPE:
                         English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                            DATE
                                           APPLICATION NO.
                                                            DATE
                      KIND
     PATENT NO.
                                           wo 2000-us26258 20001016
     wo 2001028591
                       Α2
                            20010426
                       Α3
                            20020307
     WO 2001028591
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                           20020710
                                       EP 2000-971986 20001016
     EP 1220690
                       A2
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
PRIORITY APPLN. INFO.:
                                        US 1999-159739P P 19991015
                                        WO 2000-US26258 W 20001016
     The invention provides injection vehicles suitable for administering
AB
     particulate suspensions, such as polymer-based formulations, as well as
     assocd. pharmaceutical formulations, articles of manuf., and kits. Other
     aspects of the invention included methods for producing and administering
     pharmaceutical formulations. The injection vehicles of the invention are
     superior to conventional injection vehicles in that they include a
     pseudoplastic compn. that improves injectability, which facilitates
     delivery of the desired dose. The injection vehicles of the invention
     also allow the use of smaller-bore needles than are usually necessary to
     inject polymer-based formulations, reducing the pain assocd. with
     injection of such formulations. Syringeability of ***microspheres***
     contg. proteins such as anti-rhGH Fab polymer-based formulations or VEGF,
     or other proteins and contg. Na ***hyaluronate*** was studied.
=> d his
     (FILE 'HOME' ENTERED AT 17:26:07 ON 27 AUG 2003)
```

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT

17:26:32 ON 27 AUG 2003

102649 S MICROSPHERE OR MICROPARTICLE

L8

```
2147 S POLY (W) (LACTIDE )-GLYCOLIDE)
L2
           479 S POLY (W) GLYCOLIDE
L3
           5055 S POLY (W) (LACTIC ACID)
L4
             93 S POLY (W) (LACTIC ACID)(W) CO (W) (GLYCOLIC ACID)
L5
         147014 S POLYANHYDRIDE OR POLYORTHOESTER OR POLYETHERESTER OR POLYCAPR
L6
L7
         153734 S L2 OR L3 OR L4 OR L5 OR L6
         102649 S MICROSPHERE OR MICROPARTICLE
L8
           3141 S L7 (P) L8
L9
             15 S L1 (A) (BUFFER OR SALINE)
L10
              0 S L9 (P) L10
L11
              2 S L9 (P) L1
L12
              2 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)
L13
              0 S L10 (P) L8
L14
              5 S CLELAND JEFFREY/AU
L15
              9 S LAM XANTHE/AU
L16
              6 S OKUMU FRANKLIN/AU
L17
              1 S (L15 OR L16 OR L17) AND L1 AND L8
L18
=> log y
                                                 SINCE FILE
COST IN U.S. DOLLARS
                                                                 TOTAL
                                                               SESSION
                                                      ENTRY
                                                                 83.81
                                                      83.60
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                 SINCE FILE
                                                                 TOTAL
                                                      ENTRY
                                                               SESSION
                                                                 -1.30
                                                      -1.30
CA SUBSCRIBER PRICE
```

49541 S (HYALURONIC ACID) OR HYALURONATE

STN INTERNATIONAL LOGOFF AT 17:39:45 ON 27 AUG 2003

L1